Introduction: Infections associated with medical implants pose significant challenges to healthcare, demanding the development of new effective antimicrobial strategies. This study focuses on the creation of a novel biological membrane with enhanced antimicrobial properties by with the incorporation of either vancomycin or silver nanoparticles. Methods: Pericardium samples were impregnated with either silver nanoparticles (AgNPs) or vancomycin (VAN). The antimicrobial activity of the membranes was assessed through qualitative microbiological analysis, biofilm production and animal in vivo model of infection. Histological analysis was performed on the pericardium samples, and quantitative microbiological analysis was conducted on the tissue from the animal model and biocompatibility evaluation. Statistical analyses were carried out using appropriate tests. Results: Microbiological tests confirmed both VAN and AgNP showed inhibition halos against bacteria. Histological analysis indicated minimal inflammatory response and bacterial presence in VAN and AgNP groups compared to the control group revealed reduced bacterial presence. Biomechanical testing showed that polypropylene had the lowest tensile strength, while AgNP-impregnated pericardium exhibited lower resistance than VAN-impregnated and control pericardium. Conclusion: Lyophilized and decellularized bovine pericardium as a substrate, combined with the incorporation of vancomycin or silver nanoparticles, provides a versatile platform for combating infections associated with medical implants.

Background: Heart failure is a major cause of morbidity and mortality worldwide; left ventricular diastolic dysfunction plays a leading role in this clinical context. Diastolic dysfunction may be predisposed by increased abdominal fat and, consequently, increased pericardial and epicardial adiposity. This study aimed to determine whether pericardial and epicardial fat are associated with left ventricular diastolic function. Methods: 82 patients had their abdominal circumference measured and underwent transthoracic echocardiography to measure the thickness of pericardial and epicardial fat and assess the left ventricular diastolic function. Two groups were created based on mean pericardial fat thickness (4.644 mm) and were related to abdominal circumference and echocardiographic parameters. Results: Subjects in the PF High group showed a significant decrease in septal e' (p<0.0001), lateral e' (p<0.0001) and E/A ratio (p=0.003) and a significant increase in E/e' ratio (p<0. 0001), E wave deceleration time (p=0. 013), left atrial volume (p<0.0001), LV mass (p=0.003), tricuspid regurgitant jet velocity (p<0.0001) and LV diameter (p=0.014) compared to the PF Low group. Conclusions: Measurement of abdominal circumference, pericardial and epicardial fat is an early indicator of diastolic changes with transthoracic echocardiography being the gold standard exam.

Pathological aseptic calcification is the most common form of structural valvular degeneration (SVD), leading to premature failure of heart valve bioprostheses (BHVs). The processing methods used to obtain GA-fixed pericardium-based biomaterials determine the hemodynamic characteristics and durability of BHVs. This article presents a comparative study of the effects of several processing methods on the degree of damage to the ECM of GA-fixed pericardium-based biomaterials as well as on their biostability, biocompatibility, and resistance to calcification. Based on the assumption that preservation of the native ECM structure will enable the creation of calcinosis-resistant materials, this study provides a soft biomimetic approach for the manufacture of GA-fixed biomaterials using gentle decellularization and washing methods. It has been shown that the use of soft methods for preimplantation processing of materials, ensuring maximum preservation of the intactness of the pericardial ECM, radically increases the resistance of biomaterials to calcification. The data obtained are of interest for the development of new calcinosis-resistant biomaterials for the manufacture of BHVs.